Differences in transcriptome-wide gene expression variability between familial breast cancer groups (BRCA1, BRCA2 and BRCAx) were quantified by comparing tumour-specific measurements of variability (SD, CV and MAD). This evidence concerns the gene BRCA1 and breast carcinoma.